The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast

Iryna Savelikhina (Ivano-Frankivsk, Ukraine), Mykola Ostrovskyy, Oleksandr Varunkiv, Iryna Savelikhina, Mariana Kulynych-Miskiv

Source: International Congress 2015 – New data on established treatments for asthma and COPD
Session: New data on established treatments for asthma and COPD
Session type: Thematic Poster Session
Number: 1007
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Iryna Savelikhina (Ivano-Frankivsk, Ukraine), Mykola Ostrovskyy, Oleksandr Varunkiv, Iryna Savelikhina, Mariana Kulynych-Miskiv. The role of determining the levels of collagen type IV in the management of patients with severe chronic obstructive pulmonary disease – Focus on roflumilast. Eur Respir J 2015; 46: Suppl. 59, 1007

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Effect of long-term treatment with fenspiride on clinical and functional status of patients with chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD biomarkers
Year: 2013


PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014

Detection of chronic obstructive pulmonary disease (COPD) in patients with cardio-vascular system pathology
Source: Annual Congress 2013 –COPD treatment and others
Year: 2013


Survivin in patients with chronic obstructive pulmonary disease
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015

Comparison of blood eosinophils and plasma periostin in stable and non-stable chronic obstructive pulmonary disease: How we can improve the management of our patients
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016


The economical effect of inhaler in patients with early chronic obstructive pulmonary disease
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Effects of pulmonary rehabilitation in patients with severe COPD in comparison to patients with severe interstitial lung disease
Source: Annual Congress 2013 –The best posters in pulmonary rehabilitation
Year: 2013


The role of IFN-γ in severe COPD patients with anamnestic viral-induced exacerbations before and after roflumilast treatment
Source: International Congress 2016 – Translational studies in lung disease
Year: 2016

Can roflumilast improve clinical outcomes in moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016

Regional differences in the treatment of patients with moderate COPD enrolled in a global clinical trial
Source: Annual Congress 2006 - Recent advances in the treatment of COPD
Year: 2006


The systemic inflammation and factors of coagulation in patients with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – COPD markers
Year: 2014


Current maintenance treatment of chronic obstructive pulmonary disease in China
Source: International Congress 2014 – Respiratory disease within hospital-based populations
Year: 2014


Effects of pulmonary rehabilitation on exacerbation number and severity in people with chronic obstructive pulmonary disease (COPD)
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016


Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease
Source: Eur Respir J 2001; 18: 903-908
Year: 2001



The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities)
Source: International Congress 2014 – Comorbidities
Year: 2014


Quantify comorbidities burden of chronic obstructive pulmonary disease patients using medication regimen complexity index
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016


Measurement properties of exacerbations of chronic pulmonary disease tool (EXACT) in a clinical trial of patients with moderate to severe COPD
Source: Annual Congress 2013 –Monitoring symptoms and quality of life
Year: 2013


The effect of statin therapy in patients with chronic obstructive airway disease
Source: International Congress 2015 – COPD: notable points
Year: 2015


Prevalence and effects of malnutrition in COPD patients referred for pulmonary rehabilitation
Source: Annual Congress 2013 –The best posters in chronic care
Year: 2013


The characteristic of chronic renal dysfunction in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities
Year: 2016